Cue Biopharma, Inc. CUE
$28.27
-23.70%
at last close
Market Cap$269.15 million
P/E Ratio—
Div Yield—
Volume3.54M
52-Week Range
$4.97$45.50
Analyst Ratings
- Consensus
- Buy — 1 Buy · 0 Hold · 0 Sell (1 analysts)
- Avg. Price Target
- $83.00 (+193.6% upside)
Key Stats
- Today's Range
- $23.80 – $41.50
- 50-Day Range
- $22.56 – $41.50
- 52-Week Range
- $4.97 – $45.50
- Volume
- 3.54 million shs
- Average Volume
- 306K shs
- Market Cap
- $269.15 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 116.51
- Price / Sales
- 7.15
Short Interest
- Short Interest
- 0.48%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $37.65 million
- Net Income
- $-164,108,000
- Net Margin
- -435.83%
- Return on Equity
- -7104.24%
- Debt-to-Equity
- —
About Cue Biopharma, Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
Related Stocks
Compare head-to-head: CUE vs LLY·CUE vs JNJ·CUE vs ABBV·CUE vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.